Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

What Was Tested

The trial (not phased) is built around Tirzepatide and Semaglutide.

Obesity is a growing global health problem that affects people of all ages.

It had four arms (groups): ARM 1-Semaglutide (experimental), ARM 3-Semaglutide + Exercise (experimental), ARM 4-Tirzepatide + Exercise (experimental) and ARM 2-Tirzepatide (experimental).

Drug: Semaglutide.

The registry classes the interventions as behavioral and drug.

Who Took Part

The registry lists 48 planned participants were the target.

It was open to people of any sex aged from 25 years up to 60 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Those between the ages of 25 and 60 years. Those with a body mass index (BMI) between 30 and 40 kg/m2 according to the World Health Organization (WHO) classification. Individuals who volunteered to participate in the study.

The full record lists 3 inclusion and 15 exclusion criteria; among the exclusions: individuals with a bmi greater than 40 kg/m2 according to the who classification; individuals with a charlson comorbidity index score of 3 or higher; uncontrolled arrhythmia, hypertension, heart failure, diabetes, and unstable angina pectoris.

How the Study Was Run

The set-up was randomized, parallel-group and single-blind.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

In this single-blind Tirzepatide study one party knew the assignments and the other did not.

Those kept unaware of assignments: outcomes assessor.

It started in 2025-12-29 with completion listed for 2026-10.

It ran at 1 site in Turkey (Türkiye).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Body fat-muscle ratios (Body composition) (time frame: Three months).

It also tracked 8 secondary outcomes, for example Peripheral muscle strength, Glucose profile, Functional capacity, Pulmonary function, Respiratory muscle strength and Physical activity level.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Tirzepatide and Semaglutide in 48 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Semaglutide compound page, all human trials.